Novo Nordisk achieves primary objectives of ONWARDS 1 and 6 trials with once-weekly insulin icodec demonstrating superior reduction in HbA1c vs insulin glargine U100 in ONWARDS 1
Bagsværd, Denmark, 3 June 2022 – Novo Nordisk today announced headline results from the main…
Pitches and Keynote Speakers Are Confirmed for Blue Magic Netherlands on November 17
The 34th Hong Kong International Optical Fair opens today
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Approved in Singapore, Filling Gap in Vitiligo Treatment
Payment Cards Group (A3A PayTech) Joins HKMA’s Agentic Finance Expert Group
Three Million Fewer Members, JPY97.5 Billion More Revenue: APEC Lands in Shenzhen and China’s Gym Industry Is Being Recomposed